Resources Repository
-
Resource PackPublication, Teaching Resource 2024Resource Pack: BCA in Low- and Middle-Income Countries
This resource pack, curated by the Center for Health Decision Science, includes methods papers, case …
This resource pack, curated by the Center for Health Decision Science, includes methods papers, case studies, and reference case guidelines for conducting benefit-cost analyses in low- and middle-income countries. These resources will aid advanced students and experienced practitioners in preparing these analyses. Investing in global health and development requires making difficult choices about what initiatives to fund and what level of resources to devote to each initiative. Although benefit-cost analysis is a well-established and widely…
Benefit-Cost Analysis | Health/Medicine | Global | Social Determinants | Preferences/Values | Priority Setting/Ethics | Decision Analysis | Policy/Regulation | Economics/Finance | Graduate | Doctoral | Professional | Critical Thinking/Analysis -
GuidelinesPublication 2018Latent TB Infection: Updated & Consolidated Guidelines for Programmatic Management
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation …
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens with no evidence of clinically manifest active TB. Up to one third of the world’s population is estimated to be infected with Mycobacterium tuberculosis, and on average, 5–10% of those who are infected will develop active TB disease over their lifetime. The management of LTBI involves a comprehensive package of interventions: identifying and testing those individuals…
Evidence Synthesis | Health/Medicine | Global | Infectious Diseases -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Test Performance | Health/Medicine | Global | Infectious Diseases | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Economics/Finance | North America -
Resource PortalWeb Portal, Teaching Resource 2024ImmunizationEconomics.org
ImmunizationEconomics.org is a resource for organizations and individuals involved in the field of immunization economics. …
ImmunizationEconomics.org is a resource for organizations and individuals involved in the field of immunization economics. The site was originally created in 2015 as part of the EPIC project with funding from the Bill & Melinda Gates Foundation and has key collaborators from the Harvard T.H. Chan School of Public Health, Johns Hopkins University, ThinkWell, and Results for Development. ImmunizationEconomics.org has three central aims: (1) To create a global community of practice consisting of experts in…
Costing Methods | Health/Medicine | Global | Infectious Diseases | Cost-Effectiveness Analysis | Health Systems -
ArticlePublication 2016Global Burden of Latent Tuberculosis Infection
Given the importance of controlling latent TB infection (LTBI) as part of the End TB …
Given the importance of controlling latent TB infection (LTBI) as part of the End TB Strategy for eliminating TB by 2050, the authors felt that changes in demography and scientific understanding, and progress in TB control, made it necessary to re-assess the global burden of LTBI. The authors used constructed trends in annual risk in infection to calculate the number and proportions of individuals infected, recently infected, and recently infected with isoniazid (INH)-resistant strains, aggregated…
Evidence Synthesis | Health/Medicine | Global | Infectious Diseases | Mathematical Models -
ArticlePublication 2016Using Top-Down and Bottom-Up Costing Approaches in LMICs
In the absence of routine cost data collection, estimating the incremental costs of scaling-up novel …
In the absence of routine cost data collection, estimating the incremental costs of scaling-up novel technologies in low-income and middle-income countries is a methodologically challenging and substantial empirical undertaking. Using the example of costing the scale-up of Xpert Mycobacterium tuberculosis (MTB)/resistance to riframpicin (RIF) in South Africa, the authors estimate costs, by applying two distinct approaches of bottom-up and top-down costing, together with an assessment of processes and capacity. The unit costs measured using the…
Costing Methods | Health/Medicine | Global | Infectious Diseases | Cost-Effectiveness Analysis | Health Systems | Economics/Finance -
ArticlePublication 2016Challenges of Prioritization
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and …
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and diagnostics; in addition, the evidence base drawn on for evaluating such interventions is relatively good, given the medical research industry surrounding their testing. However, with increasing success in controlling infectious diseases, many of the health challenges facing countries concern broad threats to health with multiple causes, such as obesity, where the relationship between policy action and health benefit is not…
Benefit-Cost Analysis | Health/Medicine | Global | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Chronic Disease/Risk | Mental Health | Health Systems | Economics/Finance -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Health Outcomes | Health/Medicine | Global | Infectious Diseases | Mathematical Models | Calibration/Validation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific